OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint

뉴스 본문을 불러오고 있어요.

OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint | 웨이프 WAPE

OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint

기사 요약

관련 종목

댓글 —